Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30536629 | 1.00 | F2RL1 (0.36) | F2RL1DGAT1HTR2AHTR2CHTR2B | |
| SCHEMBL1957623 | 0.81 | F2RL1 (0.39) | F2RL1DGAT1HTR2AHTR2CHTR2B | |
| SCHEMBL30536675 | 0.79 | DGAT1 (0.36) | F2RL1DGAT1HTR2AHTR2CHTR2B | |
| SCHEMBL25367415 | 0.79 | DGAT1 (0.36) | F2RL1DGAT1HTR2AHTR2CHTR2B | |
| SCHEMBL25365843 | 0.78 | DGAT1 (0.37) | F2RL1DGAT1NPC1 | |
| SCHEMBL29493774 | 0.78 | DGAT1 (0.37) | F2RL1DGAT1NPC1 | |
| SCHEMBL25367988 | 0.76 | DGAT1 (0.38) | F2RL1DGAT1ALOX5APFEN1NPC1 | |
| SCHEMBL25852658 | 0.76 | F2RL1 (0.39) | F2RL1DGAT1ALOX5APFEN1 | |
| SCHEMBL1955936 | 0.76 | DGAT1 (0.34) | F2RL1DGAT1ALOX5APFEN1NPC1 | |
| SCHEMBL31411454 | 0.75 | DGAT1 (0.38) | F2RL1DGAT1ALOX5APFEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-03-14 | — | — | US | disclosed |
| CN-116600801-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-4221701-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022072491-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | F2RL1 3430/4885DGAT1 916/4885HTR2A 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.